Cargando…
Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review
AIM: Immune checkpoint inhibitors are anti-cancer drugs associated with adverse events that result from releasing the immune system against self-antigens while attacking cancer cells. Thyroid dysfunctions are among the most common associated adverse events. MATERIALS AND METHODS: We conducted a syst...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650809/ https://www.ncbi.nlm.nih.gov/pubmed/33177863 http://dx.doi.org/10.2147/IJGM.S261433 |
_version_ | 1783607559308967936 |
---|---|
author | El Sabbagh, Rawaa Azar, Nadim S Eid, Assaad A Azar, Sami T |
author_facet | El Sabbagh, Rawaa Azar, Nadim S Eid, Assaad A Azar, Sami T |
author_sort | El Sabbagh, Rawaa |
collection | PubMed |
description | AIM: Immune checkpoint inhibitors are anti-cancer drugs associated with adverse events that result from releasing the immune system against self-antigens while attacking cancer cells. Thyroid dysfunctions are among the most common associated adverse events. MATERIALS AND METHODS: We conducted a systematic search of the literature in 2 databases: PubMed and Medline. Articles that reported thyroid adverse events of immune checkpoint inhibitors were reviewed. Thyroid disorders include hyperthyroidism and hypothyroidism and are most commonly seen with programmed cell death protein 1 and programmed death-ligand 1 inhibitors. CONCLUSIONS: Thyroid disorders are common side effects seen with check point inhibitors and are treated, depending on the clinical situation, by adequate hormonal replacement, thionamides, corticosteroids or observation only. The use of high dose corticosteroids has not been established as a treatment of thyroid toxicities. Thyroid function tests screening should be a part of baseline laboratory testing of all patients undergoing treatment with immune checkpoint inhibitors. |
format | Online Article Text |
id | pubmed-7650809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-76508092020-11-10 Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review El Sabbagh, Rawaa Azar, Nadim S Eid, Assaad A Azar, Sami T Int J Gen Med Review AIM: Immune checkpoint inhibitors are anti-cancer drugs associated with adverse events that result from releasing the immune system against self-antigens while attacking cancer cells. Thyroid dysfunctions are among the most common associated adverse events. MATERIALS AND METHODS: We conducted a systematic search of the literature in 2 databases: PubMed and Medline. Articles that reported thyroid adverse events of immune checkpoint inhibitors were reviewed. Thyroid disorders include hyperthyroidism and hypothyroidism and are most commonly seen with programmed cell death protein 1 and programmed death-ligand 1 inhibitors. CONCLUSIONS: Thyroid disorders are common side effects seen with check point inhibitors and are treated, depending on the clinical situation, by adequate hormonal replacement, thionamides, corticosteroids or observation only. The use of high dose corticosteroids has not been established as a treatment of thyroid toxicities. Thyroid function tests screening should be a part of baseline laboratory testing of all patients undergoing treatment with immune checkpoint inhibitors. Dove 2020-11-04 /pmc/articles/PMC7650809/ /pubmed/33177863 http://dx.doi.org/10.2147/IJGM.S261433 Text en © 2020 El Sabbagh et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review El Sabbagh, Rawaa Azar, Nadim S Eid, Assaad A Azar, Sami T Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review |
title | Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review |
title_full | Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review |
title_fullStr | Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review |
title_full_unstemmed | Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review |
title_short | Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review |
title_sort | thyroid dysfunctions due to immune checkpoint inhibitors: a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650809/ https://www.ncbi.nlm.nih.gov/pubmed/33177863 http://dx.doi.org/10.2147/IJGM.S261433 |
work_keys_str_mv | AT elsabbaghrawaa thyroiddysfunctionsduetoimmunecheckpointinhibitorsareview AT azarnadims thyroiddysfunctionsduetoimmunecheckpointinhibitorsareview AT eidassaada thyroiddysfunctionsduetoimmunecheckpointinhibitorsareview AT azarsamit thyroiddysfunctionsduetoimmunecheckpointinhibitorsareview |